ACQUISITIONS (Details) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended	6 Months Ended
	Apr. 30, 2024 USD ($)	Oct. 31, 2023 USD ($) Right $ / shares	Jun. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)
ACQUISITIONS
Transaction costs		$ 2,645
Acquired in-process research and development expense				$ 42,595
Zynerba Acquisition
ACQUISITIONS
Cash consideration per common stock | $ / shares		$ 1.1059
Aggregate consideration		$ 60,000
Number of contingent value right per common stock | Right		1
Contingent consideration per common stock | $ / shares		$ 2.5444
Epygenix Acquisition
ACQUISITIONS
Aggregate consideration	$ 32,686
Transaction costs	450
Asset acquisition, upfront consideration paid	35,000
Amount of fee payable upon achieving development and regulatory milestones	130,000
Amount of fees payable upon achieving sale-based milestones	$ 515,000
Acquired in-process research and development expense			$ 17,095	$ 17,095